Abstract: INFO12-TH
Cure Glomerulonephropathy Network (CureGN)
Session Information
- Informational Posters - 1
October 24, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- No subcategory defined
Authors
- Helmuth, Margaret, University of Michigan, Ann Arbor, Michigan, United States
- Smith, Abigail R., Northwestern University, Chicago, Illinois, United States
- Derebail, Vimal K., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Bomback, Andrew S., Columbia University, New York, New York, United States
- Khalid, Myda, Indiana University, Bloomington, Indiana, United States
- Sethna, Christine B., Northwell Health, New Hyde Park, New York, United States
- Gadegbeku, Crystal A., Cleveland Clinic, Cleveland, Ohio, United States
- Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States
Description
CureGN is a multi-center, prospective observational cohort study of glomerular disease funded by the NIH-NIDDK. CureGN has enrolled 2,894 participants with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA (immunoglobulin A) vasculitis with nephritis or nephropathy (IgAV-N) from 71 sites internationally since Dec. 2014.
Pediatric and adult patients biopsied within 5 years are eligible to participate. Exclusion criteria include kidney failure at enrollment, diabetes at biopsy, and glomerular disease attributed to a secondary cause. Sociodemographic, clinical, pathologic, and patient reported data collection is enriched by a diverse biorepository and digital pathology repository (DPR). Renal and non-renal outcomes are collected. Participant characteristics with median 5.8 year follow up are shown (Table 1).
CureGN supports multi-dimensional translational research by combining clinical phenotype, pathology, and outcome data with longitudinally collected DNA, RNA, blood, and urine specimens. To date, whole genome sequencing and RNA sequencing has been performed on 2,000 and 2,124 patients, respectively. The DPR can provide annotated images or quantitative scoring data from kidney biopsies for investigators, and currently stores images from 1,647 patient biopsies, 1,184 of which are scored. An online data-sharing tool (tranSMART) is available to researchers for hypothesis generation.
The study objectives support a variety of ways to identify mechanistically distinct subgroups, discover/validate biomarkers, delineate disease-specific treatment targets, and inform future therapeutic trials to advance the diagnosis, care, and outcomes of glomerular diseases. Patient input into the study is integrated via a patient advisory panel. The Career Development Group provides peer mentoring for young investigators interested in glomerular disease. The consortium has a mature infrastructure available to support ancillary study proposals and specifically invites application from Network and extramural investigators.
Funding
- NIDDK